Media coverage about Cara Therapeutics (NASDAQ:CARA) has been trending somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cara Therapeutics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.4432751769212 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern’s analysis:

Cara Therapeutics (CARA) opened at $12.55 on Thursday. The stock has a market capitalization of $401.74, a P/E ratio of -5.48 and a beta of 2.97. Cara Therapeutics has a fifty-two week low of $11.11 and a fifty-two week high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). During the same period last year, the company posted ($0.42) earnings per share. equities analysts expect that Cara Therapeutics will post -1.84 earnings per share for the current fiscal year.

Several equities research analysts recently commented on CARA shares. Scotiabank raised their target price on Cara Therapeutics from $31.00 to $31.50 and gave the stock an “outperform” rating in a research note on Tuesday, October 17th. ValuEngine cut Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, September 27th. BidaskClub raised Cara Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 2nd. Raymond James Financial raised their target price on Cara Therapeutics from $25.00 to $26.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 7th. Finally, Zacks Investment Research cut Cara Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $24.97.

In other Cara Therapeutics news, CEO Derek T. Chalmers sold 16,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $12.66, for a total value of $202,560.00. Following the transaction, the chief executive officer now owns 1,066,292 shares in the company, valued at $13,499,256.72. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Cara Therapeutics (CARA) Earns Coverage Optimism Score of 0.20” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with's FREE daily email newsletter.